Literature DB >> 3819789

Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy.

S Goda, T Hamada, S Ishimoto, T Kobayashi, I Goto, Y Kuroiwa.   

Abstract

In a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes [MELAS] who had normal mitochondrial enzyme activity, high doses of coenzyme Q10 (CoQ) were administered. Clinical improvement with decreased serum lactate and pyruvate levels was observed. Though the mechanism of action of CoQ is not known, a trial is worthwhile in patients with MELAS.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3819789     DOI： 10.1007/bf00314013

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  6 in total

1.  Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome.

Authors:  S Ogasahara; S Yorifuji; Y Nishikawa; M Takahashi; K Wada; T Hazama; Y Nakamura; S Hashimoto; N Kono; S Tarui
Journal:  Neurology       Date:  1985-03       Impact factor: 9.910

2.  Familial poliodystrophy, mitochondrial myopathy, and lactate acidemia.

Authors:  Z H Hart; C H Chang; E V Perrin; J S Neerunjun; R Ayyar
Journal:  Arch Neurol       Date:  1977-03

3.  Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome.

Authors:  S G Pavlakis; P C Phillips; S DiMauro; D C De Vivo; L P Rowland
Journal:  Ann Neurol       Date:  1984-10       Impact factor: 10.422

4.  Familial poliodystrophy, mitochondrial myopathy, and lactate acidemia.

Authors:  Y Shapira; S D Cederbaum; P A Cancilla; D Nielsen; B M Lippe
Journal:  Neurology       Date:  1975-07       Impact factor: 9.910

5.  Reversible alexia, mitochondrial myopathy, and lactic acidemia.

Authors:  R R Skoglund
Journal:  Neurology       Date:  1979-05       Impact factor: 9.910

6.  Mitochondrial encephalomyopathies: biochemical studies in two cases revealing defects in the respiratory chain.

Authors:  J A Morgan-Hughes; D J Hayes; J B Clark; D N Landon; M Swash; R J Stark; P Rudge
Journal:  Brain       Date:  1982-09       Impact factor: 13.501
  6 in total
  6 in total

1.  Cytochrome c oxidase and coenzyme Q in neuromuscular diseases: a histochemical study.

Authors:  C Doriguzzi; L Palmucci; B Pollo; T Mongini; M Maniscalco; L Chiadò-Piat; D Schiffer
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 2.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

3.  Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy.

Authors:  J M Shoffner; M T Lott; A S Voljavec; S A Soueidan; D A Costigan; D C Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

4.  Coenzyme Q in serum and muscle of 5 patients with Kearns-Sayre syndrome and 12 patients with ophthalmoplegia plus.

Authors:  S Zierz; G Jahns; F Jerusalem
Journal:  J Neurol       Date:  1989-02       Impact factor: 4.849

5.  Mitochondrial encephalomyopathy (MELAS) with mental disorder. CT, MRI and SPECT findings.

Authors:  T Suzuki; J Koizumi; H Shiraishi; N Ishikawa; K Ofuku; M Sasaki; T Hori; N Ohkoshi; I Anno
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

Review 6.  Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications.

Authors:  Gerwyn Morris; George Anderson; Michael Berk; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-06-13       Impact factor: 5.590
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.